Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1

Key Takeaway: Compass Pathways plc will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026. Management will participate in a fireside chat at 3:25pm ET, which will be available via a live audio webcast. The company focuses on developing COMP360 psilocybin for treatment-resistant depression and PTSD, aiming to provide new treatment options in mental health care.
Price reaction · baseline $8.12 (2026-11-18 close) · hit pre-market · clean, no other CMPS news in the window
day 0 close · peak
+6.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare conference.
  • Focus on innovative treatment options for mental health.
  • Breakthrough Therapy designation from the FDA.
  • Leading clinical program in treatment-resistant depression.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
6.5%
average across 4 past catalysts
Cash runway
~26 mo
Low dilution risk
Lead asset
COMP360
Phase 3 · Treatment Resistant Depression

Full Press Release Details

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET.
A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ
A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website.
About Compass Pathways
We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. We are leading the world’s largest classic psychedelic clinical program in TRD, and building upon that robust foundation, we are executing a late-stage trial evaluating COMP360 for PTSD, another condition with high unmet need. Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.
Compass is headquartered in London, UK, with a U.S. office in New Jersey.
We are driven by our purpose of unlocking pathways to be – opening futures filled with possibility. Together, we are on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery, because every journey needs a Compass.

Frequently Asked Questions

When is the Evercore Healthcare Conference?

The conference is on December 1, 2026.

What time will Compass Pathways' chat occur?

The fireside chat is scheduled for 3:25pm ET.

How can I access the webcast?

The webcast will be available at the provided link.

What is COMP360?

COMP360 is a synthetic psilocybin treatment for mental health conditions.

Last updated: Nov 19, 2026